Zinc deficiency-associated dermatitis in infants during a nationwide shortage of injectable zinc--Washington, DC, and Houston, Texas 2012-2013 by Ruktanonchai, Duke et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Pediatrics Faculty Publications Pediatrics
1-17-2014
Zinc deficiency-associated dermatitis in infants
during a nationwide shortage of injectable zinc--
Washington, DC, and Houston, Texas 2012-2013
Duke Ruktanonchai
Michael Lowe
Scott A. Norton
Tiana Garrett
Lamia Soghier
George Washington University
See next page for additional authors
Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs
Part of the Pediatrics Commons
This Journal Article is brought to you for free and open access by the Pediatrics at Health Sciences Research Commons. It has been accepted for
inclusion in Pediatrics Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.
Recommended Citation
Ruktanonchai, D., Lowe, M., Norton, S. A., Garrett, T., Soghier, L., et al. (2014). Zinc Deficiency--Associated Dermatitis in Infants
During a Nationwide Shortage of Injectable Zinc -- Washington, DC, and Houston, Texas, 2012-2013. MMWR: Morbidity &
Mortality Weekly Report, 63(2), 35-37.
Authors
Duke Ruktanonchai, Michael Lowe, Scott A. Norton, Tiana Garrett, Lamia Soghier, Edward Weiss, June
Hatfield, Jeffrey Lapinski, Steven Abrams, and Wanda Barfield
This journal article is available at Health Sciences Research Commons: https://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs/612
Morbidity and Mortality Weekly Report
MMWR / January 17, 2014 / Vol. 63 / No. 2 35
Zinc Deficiency–Associated Dermatitis in Infants During  
a Nationwide Shortage of Injectable Zinc —  
Washington, DC, and Houston, Texas, 2012–2013
Duke Ruktanonchai, MD1, Michael Lowe, PhD1, Scott A. Norton, MD2, Tiana Garrett, PhD1, Lamia Soghier, MD3, Edward Weiss, 
MD4, June Hatfield, MS3, Jeffrey Lapinski, MS3, Steven Abrams, MD4, Wanda Barfield, MD5 (Author affiliations at end of text)
Injectable zinc, a vital component of parenteral nutrition 
(PN) formulations, has been in short supply in the United 
States since late 2012. In December 2012, three premature 
infants with cholestasis hospitalized in Washington, DC, 
experienced erosive dermatitis in the diaper area and blisters on 
their extremities, a condition that can be associated with zinc 
deficiency (1). All three infants were receiving PN because they 
had extreme cholestasis and were unable to be fed by mouth or 
tube. The PN administered to each infant was zinc deficient. 
Injectable zinc normally is added to PN for premature or 
medically compromised infants (e.g., those with cholestasis) 
by the hospital pharmacy because the amount of zinc needed 
by each patient differs; however, the pharmacy had run out of 
injectable zinc. No alternatives were available; other prepara-
tions of parenteral trace elements either contained insufficient 
zinc to meet infants’ requirements or had the potential to 
cause trace element toxicity in infants with cholestasis (2). The 
dermatitis of one infant resolved after the patient was able to 
take nutrition by mouth. The other two infants were found to 
have low serum zinc levels. In January 2013, CDC was noti-
fied of four additional cases of zinc deficiency among infants 
with cholestasis who received zinc-deficient PN in a hospital 
in Houston, Texas. In collaboration with the Food and Drug 
Administration (FDA), the two hospitals obtained emergency 
shipments of injectable zinc. No additional cases were reported. 
Current injectable zinc supplies have been increasing as FDA 
collaborates with pharmaceutical companies to import emer-
gency supplies. FDA is working to establish temporary backup 
sources should future shortages occur. 
On December 18, 2012, three cases of zinc deficiency disor-
der in premature infants were diagnosed in Washington, DC. 
Among the three infants, two were born at 24 weeks’ gestation, 
and one was born at 29 weeks’ gestation. Birth weights ranged 
from 551 g to 734 g (Table). The hospital caring for the infants 
had exhausted its supply of injectable zinc in November 2012. 
Infants typically receive injectable zinc and other trace elements 
as part of PN. Because of extreme cholestasis and prematurity 
in all three infants, they were unable to receive zinc through 
oral or enteral feedings. Among cholestatic infants, other 
preparations of zinc-containing parenteral trace elements might 
cause trace element toxicity; therefore, no alternatives to the 
injectable zinc supplements were available. On January 3, 
2013, the District of Columbia Department of Health and 
CDC began case investigations. For this investigation, a case 
of zinc deficiency disorder was defined as an infant receiving 
zinc-deficient PN who had either a below-normal serum zinc 
level (<70 µg/dL) or dermatitis consistent with zinc deficiency 
disorder. The objectives of the investigation were to 1) identify 
and describe cases of zinc deficiency disorder among infants at 
greatest risk for zinc deficiency, including those who were born 
at <37 weeks’ gestation, those weighing <1,500 g at birth, and 
those with chronic or permanent gastrointestinal dysfunction; 
2) investigate the cause of the injectable zinc shortage; and 
3) describe the need to monitor symptoms of micronutrient 
deficiency during micronutrient shortages. 
After consulting with CDC, on January 10, 2013, the 
American Academy of Pediatrics (AAP) informed its members, 
which include approximately 3,000 neonatologists and 800 
neonatal intensive care units nationwide, of the injectable 
zinc shortage. The members were asked to report to AAP and 
their respective state health department if their hospitals were 
experiencing a critical shortage of zinc. AAP compiled and for-
warded all responses to CDC. On January 21, a neonatologist 
in Houston, Texas, reported four additional cases of zinc defi-
ciency disorder to CDC. Among these four infants, two were 
born at gestational ages >37 weeks; one was born at 33 weeks, 
and one was born at 25 weeks. All four infants had cholesta-
sis. Birth weights of these four infants ranged from 690 g to 
2,950 g (Table). The Houston hospital also had exhausted its 
supplies of injectable zinc in November 2012. By January 22, 
2013, a total of 17 hospitals in 10 states had reported short-
ages of zinc and other micronutrients. No additional cases of 
zinc deficiency disorder were identified. By the end of January, 
FDA was able to facilitate emergency shipment of injectable 
zinc to all 17 hospitals.
Each of the seven infants experienced zinc deficiency disorder 
after receiving zinc-deficient PN as a result of the nationwide 
shortage. The time from initiation of PN to diagnosis of zinc 
deficiency disorder ranged from 4 to 34 weeks; the exact num-
ber of weeks each infant was on zinc-deficient PN is unknown. 
Six patients were characterized as having low serum zinc levels 
(range:14–56 µg/dL [normal: 70–120 µg/dL]) and low alkaline 
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phosphatase levels (range: 32–125 U/L [normal: 150–420 U/L]). 
Alkaline phosphatase levels typically are high in patients with 
cholestasis, but the zinc deficiency disorder in these infants 
resulted in low alkaline phosphatase levels. The serum zinc 
level for the first patient was not measured because suspicion 
of zinc deficiency disorder occurred after the infant had taken 
oral feedings containing zinc and the dermatitis had resolved.
All seven infants had cholestasis. Six of the seven had derma-
titis consistent with zinc deficiency disorder, and three expe-
rienced bacterial infections. One infant experienced recurrent 
sepsis and liver failure before receiving zinc-deficient PN. This 
infant did not have dermatitis but had a low serum zinc level 
(Table). The infant died, and an autopsy was not performed. 
It is uncertain whether zinc deficiency disorder had a role in 
his death. After an emergency shipment of zinc was received by 
two hospitals, the remaining six infants received zinc in their 
PN, and all six infants improved clinically. Zinc and alkaline 
phosphatase levels returned to normal ranges, and the infants’ 
skin lesions resolved. Five of the six infants were discharged 
home. One infant remained hospitalized for 6 months for 
treatment of conditions unrelated to zinc deficiency disorder; 
that infant died in October 2013 from conditions unrelated 
to zinc deficiency disorder.
According to FDA, only two domestic manufacturers’ inject-
able zinc compounds are used in PN (American Regent and 
Hospira, Inc.). In fall 2012, American Regent informed FDA 
that it would be experiencing shortages of multiple chemicals, 
including zinc sulfate, because of delays in manufacturing. 
These delays resulted from drug quality concerns identified by 
the company, which included problems of particulate matter 
in the injectable products. FDA then contacted Hospira to 
determine whether they could meet the increase in zinc demand. 
Hospira representatives stated that the company was operating 
at maximum capacity and was unable to meet the increased 
demand; thus, the shortage continued to worsen in early 
January 2013. American Regent was able to release injectable 
zinc sulfate on January 22, but shortages continued. Hospira 
planned to release injectable zinc sulfate again by the end of 
2013. One foreign manufacturer, Laboratoire Aguettant, and its 
authorized U.S. distributor, Baxter Healthcare, in conjunction 
with the FDA, have initiated temporary importation of an inject-
able zinc solution into the U.S. market to address this shortage.
FDA is continuing to work with American Regent and Hospira 
to expedite release of injectable zinc sulfate. Information for 
health-care providers regarding the zinc shortages and expected 
release dates of new supplies of injectable zinc is provided by 
FDA on its drug shortage website (http://www.fda.gov/drugs/
drugsafety/drugshortages/ucm050792.htm). Finally, FDA is 
working with pharmaceutical companies to establish temporary 
backup sources for micronutrients should future shortages occur. 
When FDA uses regulatory discretion to allow a company to 
import a drug temporarily during a shortage, FDA ensures that 
the overseas manufacturing facility meets FDA quality standards 
and that its products (in terms of formulation and labeling) do 
not present undue risks for patients. 
Editorial Note
Zinc is an essential trace element that functions as a cofactor 
for certain enzymes involved in metabolism and cell growth 
(2,3); zinc supports immune function, protein metabolism, 
development of the gastrointestinal tract, and genetic processes 
(3). Acute zinc deficiency disorder is characterized by dermati-
tis around the limbs and body orifices, diarrhea, and impaired 
immune function, whereas chronic zinc deficiency disorder can 
lead to liver or kidney failure (2). A rare genetic disorder, acro-
dermatitis enteropathica, shares the same clinical manifestations 
TABLE. Seven infants with physician-diagnosed zinc deficiency disorder, by selected characteristics — Washington, DC, and Houston, Texas, 
2012–2013
Patient Sex
Gestational 
age (wks)
Birth 
weight (g) Cholestasis
Race/
Ethnicity
Received
PN Dermatitis
PN duration 
before 
diagnosis 
(wks)
Serum 
zinc level 
(µg/dL)*
Serum  
alkaline 
phosphatase 
level (U/L)†
Bacterial 
infection
Infant 
death
1 M 24 734 Yes Black, non-Hispanic Yes Yes 10 NA 192 No No
2 M 24 673 Yes Black, non-Hispanic Yes Yes 15 14 62 No No
3 F 29 551 Yes Black, non-Hispanic Yes Yes 10 56 32 No No
4 M 37 2,950 Yes White, Hispanic Yes Yes 18 16 74 No No
5 M 25 690 Yes White, non-Hispanic Yes Yes 34 41 73 Yes§ Yes
6 F 37 2,620 Yes White, Hispanic Yes Yes 5 25 110 Yes¶ Yes
7 M 33 1,599 Yes Black, Hispanic Yes No 4 34 92 Yes** No
Abbreviations: PN = parenteral nutrition; NA = not available.
 * Lowest serum zinc level measured by laboratory testing; normal range = 70–120 μg/dL.
 † Lowest serum alkaline phosphatase level measured by laboratory testing; normal range = 150–420 U/L.
 § Staphylococcus aureus.
 ¶ Methicillin-resistant Staphylococcus aureus.
 ** Escherichia coli and Kluyvera ascorbata. 
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as acute zinc deficiency disorder but is a metabolic disorder of 
zinc absorption. Zinc is a standard component in PN. Premature 
infants administered PN require 400 µg/kg/body weight/day 
of zinc to maintain serum levels and promote growth, whereas 
200 µg/kg/body weight/day of zinc is sufficient for full-term 
infants on PN (4). Additionally, PN might be needed for pro-
longed periods for very low birth weight infants (<1,500 g) and 
infants with chronic gastrointestinal dysfunction.
Studies have reported progressively decreasing serum zinc 
levels among infants on zinc-deficient PN, particularly prema-
ture infants and low birth weight infants (3,5). Although zinc 
deficiency disorder can have serious health implications among 
all age groups, infants are particularly vulnerable because their 
systemic zinc reserves are not fully developed and they are 
totally dependent on breast milk or formula. Therefore, the 
American Society for Clinical Nutrition recommends adding 
injectable zinc to PN for all infants and children, with priority 
for those who are premature, have low birth weight, or have 
chronic gastrointestinal dysfunction (4).
Zinc deficiencies among infants are difficult to identify for 
multiple reasons, including nonspecific signs and symptoms. The 
most common signs of zinc deficiency disorder include dermati-
tis and growth impairment, which can be attributed to multiple 
causes. Zinc deficiency disorder–associated dermatitis, which 
is a physical manifestation, is present in only the most severe 
cases. For premature infants, withdrawl of the amount of blood 
required to measure the serum zinc level might compromise the 
health of the infant; therefore, routine testing is not performed, 
which might explain, in part, why no other cases were reported.
Physicians who prescribe PN should recognize the potential 
risks for micronutrient deficiency, including zinc deficiency, 
among premature infants who require increased amounts or are 
unable to receive adequate doses. During shortages, clinicians 
might need to reserve micronutrients for the most vulnerable 
populations. According to FDA, shortages also are ongoing 
for other PN micronutrient components (e.g., selenium, 
chromium, and copper); FDA is working with manufacturers 
to prioritize which micronutrients to produce and to identify 
other sources for the micronutrients. Until the manufacture 
of these micronutrients increases, shortages will continue. 
Hospitals with limited stocks of injectable zinc should consider 
reserving available supplies for infants with the highest risk for 
deficiency. Whenever PN without the standard micronutrients 
is administered to patients, either as a result of shortages or 
other considerations, monitoring for signs and symptoms 
of micronutrient deficiencies is recommended. Health-care 
providers should always consider the specific clinical situation 
when applying these guidelines for individual clinical care.
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What is already known on this topic?
Nationwide shortages of parenteral micronutrients have 
continued to occur in recent years. These shortages can lead to 
clinically significant micronutrient deficiencies among patients 
who depend on prolonged parenteral nutrition. Premature 
infants are especially vulnerable, and certain micronutrient 
deficiencies can be lethal.
What is added by this report?
The nationwide shortage of injectable zinc that began in late 
2012 led to seven reported cases of zinc deficiency disorder in 
vulnerable infants. Among these infants, six experienced severe 
dermatitis, and three experienced invasive bacterial infections. 
The Food and Drug Administration is now temporarily permit-
ting the importation and sale of an injectable zinc product. 
What are the implications for public health practice?
Hospitals with limited stocks of injectable zinc should consider 
reserving supplies for infants with the highest risk for deficiency 
(e.g., those who are premature [born at <37 weeks’ gestation] or 
have very low birth weight [<1,500 g] and those with chronic or 
permanent gastrointestinal dysfunction). If shortages occur, 
monitoring patients on parenteral nutrition for signs and 
symptoms of micronutrient deficiencies is crucial.
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